Avalo Therapeutics prices $375M public offering to fund clinical trials of IL-1β treatment abdakibart.

Avalo Therapeutics announced a $375 million public offering of common stock and pre-funded warrants priced at $17.75 per share to advance the clinical development of its IL-1β monoclonal antibody treatment, abdakibart. The offering includes 19.73 million shares and 1.4 million pre-funded warrants, with an option for underwriters to buy an additional 3.17 million shares. Proceeds will support Phase 3 trials and general corporate purposes. The offering is expected to close on May 7, 2026, and is managed by several major investment banks.